作者: Steven Buechler
DOI:
关键词: Internal medicine 、 Test (assessment) 、 Patient population 、 Pathology 、 Disease 、 Oncology 、 Lung 、 Cancer 、 Estrogen receptor 、 Medicine 、 Breast cancer
摘要: Disclosed is an accelerated progression relapse test for use in the prognosis of disease states. According to disclosed herein, it can be determined whether a patient would benefit from treatment state or patient's not have high probability with additional treatment. In particular, useful determining cancer (breast, colon, lung, etc). For example, invention used determine estrogen receptor positive (ER+) breast patients. ER+ patients, four genetic probes are employed that target MK167, CDC6, and SPAG5 gene products. The stratifies population into two groups, low expression group identifying less likely measures, group, more measures.